“The closing of this merger marks a significant milestone, since the combined company is well-positioned to become a leader in cancer immunotherapy, with potentially transformative therapies,” said Peter Hoang, CEO of Marker Therapeutics, Inc.
Learn more about Marker Therapeutics, Inc. by going to markertherapeutics.com
Peter L. Hoang, President and CEO of TapImmune, stated, “I am delighted that the U.S. Department of Defense has again chosen to support our technology and therapeutic platform with another funding commitment.
Peter L. Hoang will be presenting at the 2018 Cantor Global Healthcare Conference and the Sachs Associates 18th Annual Biotech in Europe Forum. Webcast will be available for both events.
Peter L. Hoang will be presenting at the 2018 Janney Healthcare Conference.
TapImmune today announced that it has entered into security purchase agreements with certain institutional and accredited investors in connection with a private placement of its equity securities. The private placement will be led by New Enterprise Associates (NEA) with participation from Aisling Capital and Perceptive Advisors, among other new and existing investors.
TapImmune today announced that its President and CEO, Peter L. Hoang, will present at the Jefferies 2018 Global Healthcare Conference taking place June 5-8, 2018, in New York City.
TapImmune today announced that its President and CEO, Peter Hoang, will participate in a panel discussion and give a company presentation at the 2018 Sachs Associates Immuno-Oncology BD&L and Investment Forum, held June 1, 2018, at the Waldorf Astoria Chicago Hotel.
TapImmune Inc. (NASDAQ: TPIV) announced today that Peter Hoang, President and CEO, will host a video webinar and slide presentation to discuss the details of the proposed merger with Marker Therapeutics, Inc., on Thursday, May 24, 2018, at 4:05 p.m. EST. The webinar will be followed by a live Q&A session.
TapImmune today announced that it has expanded its recently formed Scientific Advisory Board (SAB), which will become effective in conjunction with the proposed merger between the Company and Marker Therapeutics, Inc., and will support the continued clinical development of the Company’s transformative, non-genetically engineered, multi-antigen T cell therapy platform.
It is great to welcome renowned thought leaders Dr. Cliona M. Rooney, Dr. Helen Heslop, current president of the American Society for Gene and Cell Therapy, and former President of ASGCT, Dr. Malcolm Brenner to the Scientific Advisory Board that will become effective in conjunction with the proposed merger between TapImmune and Marker Therapeutics, Inc.